Related Experiment Video
Updated: May 25, 2026

08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Brain monoamine systems in multiple system atrophy: a positron emission tomography study.
Stephanie J Lewis1, Nicola Pavese, Maria Rivero-Bosch
1Centre for Neuroscience, Dept of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
Neurobiology of Disease
|January 24, 2012
Summary
18F-dopa PET imaging reveals widespread neurodegeneration in multiple system atrophy (MSA) patients, affecting both striatal and extrastriatal regions. This contrasts with Parkinson's disease (PD), showing more localized basal ganglia dysfunction in early stages.
Area of Science:
- Neuroimaging
- Neurology
- Molecular Imaging
Background:
- Multiple system atrophy (MSA) is characterized by subcortical neurodegeneration.
- In vivo assessment of monoaminergic pathways is crucial for understanding MSA pathophysiology.
Purpose of the Study:
- To investigate in vivo changes in dopamine, noradrenaline, and serotonin transmission in MSA using 18F-dopa PET.
- To compare the extent of neurodegeneration in MSA with idiopathic Parkinson's disease (PD).
Main Methods:
- 18F-dopa Positron Emission Tomography (PET) was employed.
- 14 MSA patients, 10 PD patients, and 10 healthy controls were studied.
- 18F-dopa uptake was measured in 13 brain regions.
Main Results:
- MSA patients exhibited reduced 18F-dopa uptake in the putamen, caudate nucleus, ventral striatum, globus pallidus externa, and red nucleus compared to controls.
- PD patients showed decreased uptake only in the putamen, caudate nucleus, and ventral striatum.
- MSA patients with orthostatic hypotension had lower 18F-dopa uptake in the locus coeruleus.
Conclusions:
- 18F-dopa PET demonstrates more extensive basal ganglia dysfunction in MSA than in PD.
- Extrastriatal monoaminergic deficits in the red nucleus and locus coeruleus are detectable in MSA.
- Unlike PD, MSA does not show early compensatory increases in regional 18F-dopa uptake.
